Cartesian Therapeutics, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last report1 of 6 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
+4.91%
vs ±16.9% implied · ×0.29
shaded = implied · ▲▼ = realized
Cartesian Therapeutics has 5 disclosed suppliers and 3 disclosed customers in SEC filings.
SentenceIn September 2023, we entered into the Biogen Agreement with Biogen to research, develop, make, use, offer, sell and import products or processes containing or using an engineering T-cell modified with an mRNA comprising, or encoding a protein comprising, certain sequences licensed under the Biogen Agreement for the prevention, treatment, palliation and management of autoimmune diseases and disorders, excluding cancers, neoplastic disorders, and paraneoplastic disorders.
SentenceIn October 2021, we entered into an Exclusive License Agreement with Genovis AB (publ.), or Genovis, or the Genovis Agreement, and paid Genovis a $4.0 million one-time upfront payment.
RNAC 10-Kaccession 0001453687-26-000064
SentenceThe increase was primarily due to increased expenses reimbursable under the grant from the National Institute of Neurological Disorders and Stroke of the National Institutes of Health incurred during the year ended December 31, 2025, for which we received funding approval during the year ended December 31, 2024.
RNAC 10-Kaccession 0001453687-26-000064
SentenceAdditionally, we have in the past received grant funding from the National Institutes of Health, or NIH, and under the terms of previously awarded grants we expect to continue to receive grant funding from the NIH.
RNAC 10-Kaccession 0001453687-26-000064
SentenceIn connection with our entry into the NCI Agreement, we paid to NCI a one-time $0.1 million license royalty payment.
RNAC 10-Kaccession 0001453687-26-000064
SentenceUnder this agreement, Astellas obtained the sole and exclusive right to commercialize Xork for use in Pompe disease in combination with an Astellas gene therapy investigational or authorized product, with a current focus on AT845.
RNAC 10-Kaccession 0001453687-26-000064
Sobi paid us a one-time, upfront payment of $75.0 million, and upon the closing of a private placement of our common stock to Sobi at a price of $138.468 per share, we received an additional $25.0 million from Sobi.
RNAC 10-Kaccession 0001453687-26-000064
SentencePursuant to the Sobi License, Sobi agreed to make milestone payments totaling up to $630.0 million to us upon the achievement of various development and regulatory milestones and, if commercialized, sales thresholds for annual net sales of NASP, and tiered royalty payments ranging from the low double digits on the lowest sales tier to the high teens on the highest sales tier.
RNAC 10-Kaccession 0001453687-26-000064
Cartesian Therapeutics, Inc.
6.55
−0.20 · −2.91%
post 6.55 0.00%
Linked news
NewsExpected move
No implied move.